MARKET

MBRX

MBRX

Moleculin
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.270
+0.707
+125.70%
After Hours: 1.250 -0.02 -1.57% 19:59 04/08 EDT
OPEN
1.630
PREV CLOSE
0.5627
HIGH
1.970
LOW
1.120
VOLUME
169.91M
TURNOVER
--
52 WEEK HIGH
3.150
52 WEEK LOW
0.3230
MARKET CAP
67.60M
P/E (TTM)
-3.7145
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average MBRX stock price target is 3.333 with a high estimate of 5.00 and a low estimate of 2.000.

EPS

MBRX News

More
  • Mid-Afternoon Market Update: Dow Surges Over 600 Points; Moleculin Biotech Shares Climb
  • Benzinga · 9h ago
  • NYMT, MITT, EHTH and DPW among midday movers
  • Seeking Alpha - Article · 11h ago
  • Mid-Day Market Update: Crude Oil Up 5%; Zomedica Pharmaceuticals Shares Plunge
  • Benzinga · 11h ago
  • Why Moleculin Biotech's Stock Is Trading Higher Today
  • Benzinga · 13h ago

Industry

Pharmaceuticals
+2.77%
Pharmaceuticals & Medical Research
+2.82%

Hot Stocks

Symbol
Price
%Change

About MBRX

Moleculin Biotech, Inc. is a preclinical-stage pharmaceutical company. The Company is focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, which it refers to as Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). Annamycin is a Phase II clinical-stage anthracycline and liposome formulated anthracycline that has been designed to eliminate cardiotoxicity and avoid the multidrug resistance mechanisms. It has over two other drug development projects in progress, one involving a portfolio of small molecules, which it refers to as the WP1066 Portfolio, focused on the modulation of key oncogenic transcription factors involved in the progression of cancer, and the WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer in general, and glioblastoma. As of April 3, 2017, it had not generated any revenue from its operations.
More

Webull offers kinds of Moleculin Biotech Inc stock information, including NASDAQ:MBRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MBRX stock news, and many more online research tools to help you make informed decisions.